Cerebrolysin

Cerebrolysin is a neuropeptide preparation composed of low-molecular-weight peptides and free amino acids produced by the enzymatic breakdown of purified pig brain proteins ^[2][4]. It is designed to mimic the action of endogenous neurotrophic factors on brain protection and repair, and molecular analysis of the mixture has identified active peptide fragments corresponding to signaling molecules such as nerve growth factor and other neuropeptides ^[3]. Manufactured by EVER Neuro Pharma, it is administered parenterally as a standardized solution ^[4].

The preparation is widely used in the treatment of acute ischaemic stroke, dementia including Alzheimer's disease, and traumatic brain injury across Russia, Eastern Europe, China, and other Asian and post-Soviet countries, where it has been part of neurological practice for decades ^[4]. Its rationale rests on the central role of neurotrophic factors in the pathophysiology of these disorders, which makes agents that resemble or upregulate them attractive therapeutic candidates ^[1].

Research applications span neuroprotection, neuroregeneration, neurogenesis, and neuroplasticity, studied in both cell and animal models and in clinical trials ^[1][2]. The clinical evidence is mixed: a Cochrane systematic review and an independent meta-analysis of randomized controlled trials in acute ischaemic stroke did not demonstrate clear clinical benefit on functional outcomes, and the Cochrane review noted an increase in non-fatal serious adverse events, though overall mortality was unchanged ^[4][5]. Cerebrolysin is an approved medicine in the countries where it is marketed and is supplied as an injectable solution ^[4].

Generally well tolerated in trials, with the main issues being mild injection-site reactions and occasional dizziness, headache or a hot, flushed feeling, plus rare allergic reactions. Because it is a brain-derived biological, source and purity genuinely matter and there is a theoretical immune or allergy risk. Avoid it if you react to the product, treat self-injection of research-grade material as a real hazard, and ideally use it under medical supervision.

The Cerebrolysin product information advises against concurrent use with monoamine oxidase inhibitors because of the risk of additive or excessive stimulation, recommending a dose reduction or interruption of the MAOI if combined. The label also states that Cerebrolysin must not be mixed in the same infusion with balanced amino acid solutions, since combining it with a supplementary amino acid load could create an imbalance, and it is chemically incompatible with solutions that alter pH (for example those containing lipids) or with vitamin-containing infusions. Caution is advised when combining with antidepressants, where the manufacturer suggests reducing the antidepressant dose to avoid additive effects. Beyond these label statements there is little formal pharmacokinetic interaction data for this peptide preparation. This is research information, not medical advice.

Checking a whole stack? Run it through interactions + stacks.

Cerebrolysin is a peptide preparation produced by the controlled enzymatic breakdown of purified porcine brain proteins into a standardized mixture of low-molecular-weight neuropeptides and free amino acids. Its origins trace back to the mid-twentieth century, and it has been manufactured for decades by the Austrian company EVER Neuro Pharma (formerly Ebewe). Over that long history it has been adopted widely across Europe, Asia, and the states of the former Soviet Union as a treatment for stroke, dementia, and traumatic brain injury. Molecular analyses have since confirmed that the preparation contains active fragments resembling endogenous neurotrophic factors, providing a biochemical basis for its longstanding clinical use.

Cerebrolysin is one of the most established neurotrophic therapies in clinical practice outside North America, valued for a mechanism that mimics the brain's own growth factors to support neuronal protection, repair, and plasticity. Its biological activity is well characterized in preclinical models, where it has been shown to reduce amyloid burden, limit apoptosis, and promote neurogenesis, which sustains ongoing research interest in stroke, dementia, and brain injury. Clinicians in many countries regard it as a generally well-tolerated adjunct with a favorable safety record. A balanced view recognizes that pooled clinical trial evidence, including Cochrane reviews in stroke and vascular dementia, has been mixed and often of limited quality, which is precisely what continues to drive rigorous study of where it helps most.